Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Time trends in primary HIV-1 drug resistance among recently infected persons.

Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO.

JAMA. 2002 Jul 10;288(2):181-8.

PMID:
12095382
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

HIV-1 drug resistance in newly infected individuals.

Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M.

JAMA. 1999 Sep 22-29;282(12):1135-41.

PMID:
10501116
4.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
5.

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.

Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M.

AIDS. 2002 Jul 26;16(11):1511-9.

PMID:
12131189
6.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD.

JAMA. 1999 Sep 22-29;282(12):1142-9.

PMID:
10501117
7.

Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.

Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S.

J Med Virol. 2007 Sep;79(9):1261-9.

PMID:
17607781
8.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
9.

HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83-8.

PMID:
19323038
10.

Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.

Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E.

AIDS. 2003 Jul;17 Suppl 3:S39-48.

PMID:
14565608
11.

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP.

AIDS. 2000 Jan 28;14(2):F17-23.

PMID:
10708278
12.

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.

AIDS. 1999 Jul 30;13(11):F71-7.

PMID:
10449277
13.

Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.

Kleyn TJ, Liedtke MD, Harrison DL, Lockhart SM, Salvaggio MR, Ripley TL, Rathbun RC.

Ann Pharmacother. 2014 Apr;48(4):470-5. doi: 10.1177/1060028013519246. Epub 2014 Jan 28.

PMID:
24473489
14.
15.

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.

Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, Leal M, Soriano V; ERASE-3 Group.

AIDS. 2001 Sep 28;15(14):1894-6.

PMID:
11579258
16.

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.

Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A.

AIDS. 2002 May 3;16(7):1039-44.

PMID:
11953470
17.

Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.

Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sá CA, Machado DM, Succi RC, Tanuri A.

J Clin Microbiol. 2002 Dec;40(12):4512-9.

18.

Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.

Pilcher CD, Perkins MD, Fiscus SA, Johnston DM, Dietze R, Duque UH, Zago AM, Assad-Antunes F, Eron JJ.

J Infect Dis. 1999 May;179(5):1259-63.

19.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95. Epub 2004 Apr 13.

20.

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B.

AIDS. 2000 May 26;14(8):1009-15.

PMID:
10853983
Items per page

Supplemental Content

Write to the Help Desk